etoposide has been researched along with gsk-2816126 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Azabdaftari, G; Dalimov, Z; Ellis, L; Hu, Q; Kirk, JS; Ku, S; Lasorsa, E; Pili, R; Ramakrishnan, S; Schaarschuch, K; Wang, J | 1 |
1 other study(ies) available for etoposide and gsk-2816126
| Article | Year |
|---|---|
Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Disease-Free Survival; DNA Topoisomerases, Type II; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Epigenesis, Genetic; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Indoles; Male; Mice, Inbred C57BL; Poly-ADP-Ribose Binding Proteins; Polycomb Repressive Complex 2; Precision Medicine; Predictive Value of Tests; Prostatic Neoplasms; Pyridones; RNA, Messenger; Time Factors; Topoisomerase II Inhibitors; Up-Regulation; Xenograft Model Antitumor Assays | 2015 |